

Association between antibiotic exposure during pregnancy and postpartum
depressive symptoms: The Japan Environment and Children's Study
(妊娠中の抗菌薬使用と産後うつ症状の関係について：エコチル調査)

千葉大学大学院医学薬学府
先進予防医学共同専攻
(主任：森千里教授)
木阪 有美

1 **ABSTRACT**

2 Postpartum depressive symptoms (PDS) are a common mental health condition among women
3 after delivery. Although various causative factors have been reported, PDS remains a challenging
4 condition to predict and prevent. The disruption of the gut microbiota due to antibiotic exposure
5 has been reported to affect psychiatric conditions. Similarly, previous research suggests that
6 antibiotic exposure during pregnancy could be related to PDS. Therefore, this prospective study
7 examines the association between antibiotic exposure during pregnancy and PDS for 6 months
8 after delivery. Data were obtained from 65,272 mothers from the Japan Environment and
9 Children’s Study, a prospective birth cohort study. The ratios of maternal PDS at 1 and 6 months
10 after delivery were 12.3% and 10.1%, respectively. During pregnancy, 10.7% of women took
11 antibiotics orally. Antibiotic exposure during pregnancy was associated with an increased risk of
12 PDS only at 6 months after delivery (OR = 1.13, 95% CI [1.00, 1.26]), adjusted for potential
13 confounding factors. An increase in Edinburgh Postnatal Depression Scale scores in relation to
14 antibiotic exposure during pregnancy was primarily observed via psychological distress during
15 pregnancy. Although a causal link was not established, antibiotic exposure during pregnancy
16 may be a contributing risk factor for PDS. Therefore, when antibiotic administration is required,
17 clinical practitioners and perinatal care providers should consider the potential risk for PDS.

18

19 **No Patient or Public Contribution**

20 There was no patient or public contribution in this study, as the authors used secondary data
21 originally collected for the Japan Environment and Children’s Study.

22

23 **1 INTRODUCTION**

24 Anxiety disorder and depression during pregnancy and the postpartum period affect approximately
25 7–25% of the women who have given births. Mental disorders are a serious perinatal public health
26 concern (Adynski et al., 2019; Beck, 2006; Ghaedrahmati et al., 2017; Halbreich & Karkun, 2006;
27 Kettunen et al., 2014; Klainin & Arthur, 2009; World Health Organization (WHO), 2019). Globally,
28 suicide is the second leading cause of mortality in the first year after delivery, accounting for 20%
29 of the deaths among postpartum women (Payne & Maguire, 2019; Wisner et al., 2019). In Japan,
30 suicide was the leading cause of maternal death during pregnancy until 1 year after delivery
31 between 2015 and 2016 (Ministry of Health, Labour and Welfare, 2019). Current studies indicate
32 that postpartum depressive symptoms (PDS) affect mothers and their family members in different
33 ways, lowering their quality of life and influencing the long-term emotional, intellectual, and
34 cognitive development of the offspring including newborns; these factors can negatively affect
35 them in the early stages (Kikuchi et al., 2021; Norhayati et al., 2015; WHO, 2019). Furthermore,
36 the children of mothers with anxiety were twice at risk of attention-deficit/hyperactivity disorder
37 at 4 and 7 years of age (Fawcett et al., 2019). The impact of PDS on mothers and their family
38 members can be detrimental; thus, identifying at-risk women and implementing preventive
39 measures are necessary (Klainin & Arthur, 2009; O’Hara & McCabe, 2013; Righetti-Veltima et
40 al., 2003).

41 Although many studies have tried to identify the causes of PDS, the pathogenesis and
42 associated risk factors are not fully understood (Gelaye et al., 2016; Milgrom et al., 2008). Various
43 risk factors for PDS have been identified, including physical and biological (e.g., poor physical
44 health, premenstrual symptoms), psychological (e.g., antenatal depression and anxiety, previous
45 psychiatric illness, depression during pregnancy, poor marital relationship, stressful life events),

46 obstetric and pediatric (e.g., unplanned pregnancy, mode of delivery, parity), socioeconomic (e.g.,
47 maternal age, education, income), and cultural factors (Adynski et al., 2019; Kettunen et al., 2014;
48 Klainin & Arthur, 2009; Norhayati et al., 2015). Despite the increasing evidence on the risk factors
49 affecting the pathogenesis of PDS, effective PDS prediction and intervention remain challenging.

50 Recently, the association between the gut microbiota and the host's health has become
51 more relevant due to increased research efforts. The gut microbiota forms a network with various
52 parts of the nervous system, called gut-brain communication (covariant; Cryan & Dinan, 2012;
53 Mayer et al., 2015; Rhee et al., 2009). Several research reports suggest that changes in the gut
54 microbiome increase the risk of neuropsychiatric disorders, such as depression, anxiety, and even
55 schizophrenia (Evrensel & Ceylan, 2015; Foster & McVey Neufeld, 2013; Klein-Petersen et al.,
56 2021; Rieder et al., 2017). The gut microbiota plays an important role in stabilizing a host's mental
57 status. According to animal experiments, when the gut microbiota is disrupted, the hosts
58 experience anxiety and depression (Crumevolle-Arias et al., 2014; Jang et al., 2018). Disruption
59 of the microbiota in humans can be caused by exposure to various external factors, such as toxins,
60 drugs, food, and pathogens (Carding et al., 2015). It has been also reported that antibiotic treatment
61 affects the microbiome (Ferrer et al., 2017; Schwartz et al., 2020). The research results suggesting
62 that antibiotic treatment affects the microbiome are of serious concern because antibiotics are the
63 most common drugs prescribed over the perinatal period (Blaser, 2016). Approximately 62% of
64 pregnant women take medications and as many as one quarter take antibiotics (Santos et al., 2012;
65 Smolina et al., 2015). The most frequent indication for antibiotic prescription during pregnancy is
66 urinary tract infection, which affects approximately 8% of all pregnant women (Ailes et al., 2018).
67 A U.S. study found a possible connection between maternal antibiotic exposure intrapartum
68 through 14 days postpartum and the risk of PDS within the first 6 months after delivery (Murphy

69 et al., 2018). Another prospective cohort study of antibiotic exposure and PDS was recently
70 conducted in Australia and the researchers' initial analysis of antenatal depression (but not PDS)
71 was published (Pouranayatihosseiniabad et al., 2023, 2024).

72 PDS is, thus, a growing concern and antibiotic prescriptions during pregnancy have
73 increased since 2000 (Murphy et al., 2018). However, no study has investigated the relationship
74 between antibiotic exposure during pregnancy and PDS other than Murphy et al. (2018). Hence
75 this study examines whether antibiotic exposure during pregnancy is associated with PDS, using
76 data from the Japan Environment and Children's Study (JECS), a large-scale nationwide cohort
77 study. Additionally, it is common for mothers with PDS to experience depression during pregnancy
78 (Beck, 2006; Dubber et al., 2015; Kettunen et al., 2014). Psychological distress during pregnancy
79 has been associated with developing PDS (Khanlari et al., 2019; Milgrom et al., 2008). Antibiotic
80 exposure has been associated with changes in the gut microbiome, which itself is associated with
81 anxiety and depression (Evrensel & Ceylan, 2015; Foster & McVey Neufeld, 2013; Klein-Petersen
82 et al., 2021; Rieder et al., 2017). Hence, the mediation of psychological distress during pregnancy
83 and antibiotic exposure along with PDS is also examined. This study provides new insights
84 regarding antibiotic exposure and maternal mental health, highlighting the need for further
85 research in this area.

86

87 **2 METHODS**

88 **2.1 Study design and participants**

89 The JECS is a nationwide government-funded birth cohort study led by the Ministry of the
90 Environment of Japan. Its goal is "to identify environmental factors that affect children's health
91 and development in order to help decision makers design better chemical risk management

92 strategies” (Kawamoto et al., page 2, 2014). The study focuses on the effect of exposure to
93 chemical substances during the fetal period and/or early childhood. Expectant mothers from 15
94 regions throughout Japan were recruited to participate in the JECS between January 2011 and
95 March 2014. In total, 103,062 pregnant women were enrolled. Please refer to Kawamoto et al.
96 (2014) for the study design details.

97 This study used the JECS-an-20180131 dataset (JECS’s fixed data up to 1 year after
98 birth, released in March 2018), which includes data during pregnancy and at 1 and 6 months after
99 delivery (Figure 1). Health and medical information were collected from medical record
100 transcriptions. In this study, antibiotic use, PDS, and psychological distress were considered as
101 exposure, outcome, and potential contributing factors, respectively.

102 The JECS protocol was approved by the Institutional Review Board of Epidemiological
103 Studies of the Ministry of the Environment and the ethics committees of all participating
104 institutions. The JECS was conducted in accordance with the Declaration of Helsinki and its
105 future amendments and other relevant national regulations and guidelines. Written informed
106 consent was obtained from all participating mothers.

107

108 **2.2 Assessment of postpartum depressive symptoms**

109 The Edinburgh Postnatal Depression Scale (EPDS; Cox et al., 1987), validated for the Japanese
110 population (Okano et al., 1996), was used to assess PDS at 1 and 6 months postpartum. The
111 EPDS is a 10-item screening instrument that measures depressive symptoms experienced within
112 the previous 7 days. Responses were rated on a four-point scale, and the cumulative scores
113 ranged from 0 to 30. Higher scores indicated more severe symptoms. Okano et al. (1996)
114 reported that the Cronbach’s alphas of the Japanese version of the EPDS at 1 and 3 months

115 postpartum were 0.668 and 0.742, respectively, which indicates moderate reliability. In this
116 study, the Cronbach's alphas were 0.805 and 0.802 at 1 and 6 months postpartum, respectively.
117 Although Cox et al. (1987) suggested that an EPDS score of 12/13 is the cut-off value for
118 depressive illness, Okano et al. (1996) reported that a score of 8/9 is an appropriate cut-off for
119 PDS in the Japanese population, with 75% sensitivity and 93% specificity. Therefore, in this
120 study, an EPDS score of ≥ 9 indicated PDS.

121

122 **2.3 Antibiotic exposure**

123 Prenatal antibiotic exposure was defined as the intake of antimicrobial agents during pregnancy.
124 Information was collected via first interview questionnaires administered to mothers after
125 enrollment (T1 = Term 1) and during mid-late pregnancy (T2 = Term 2) (Figure 1). In this study,
126 antibiotic exposure was defined as a record of "antibiotic use since the confirmation of
127 pregnancy until the enrollment" in the questionnaires. Answers about medication use were
128 recorded by research coordinators based on a medication list.

129

130 **2.4 Covariates and mediating variables**

131 Based on previous studies on PDS, biological plausibility, and directed acyclic graphs, the
132 following covariates were selected and included in the multivariate analysis: age, education,
133 household income, marital status, parity, smoking habits, alcohol consumption habits, energy
134 intake, complications during pregnancy or delivery, multiple pregnancies, low birth weight, and
135 physical anomalies in newborns. In addition, to eliminate the effects of other medications used in
136 combination with antibiotics, antipyretic/analgesic drug use during pregnancy was selected as a
137 covariate. Considering PDS's association with the gut microbiota, a history of gastrointestinal

138 diseases (e.g., gastritis, gastric ulcer, duodenal ulcer, irritable bowel syndrome, Crohn’s disease,
139 or ulcerative colitis) was also selected as a covariate. Energy intake was calculated using data
140 obtained from food frequency questionnaires validated in the Japan Public Health Center-based
141 Prospective Study for the Next Generation (Yokoyama et al., 2016). Psychological distress was
142 assessed using the six-item Kessler Psychological Distress Scale (K6) validated for the Japanese
143 population (Furukawa et al., 2008; Kessler et al., 2002). Responses were rated on a five-point
144 scale, with the total score ranging from 0 to 24 points. Mothers completed the K6 questionnaire
145 during mid-late pregnancy regarding their psychological status in the past one month (Figure 1).
146 A priori, we planned to evaluate whether the association between antibiotic exposure during
147 pregnancy and postpartum depressive tendencies was mediated by psychological distress during
148 pregnancy; for this, we conducted a path analysis with the K6 scores as an intermediate variable.
149 Table 1 shows the categorical distributions of the covariates.

150

151 **2.5 Statistical analysis**

152 Binomial logistic regression analysis was performed to estimate the odds ratios (ORs) for PDS
153 observed at 1 and 6 months after delivery in relation to antibiotic exposure. Multinomial logistic
154 regression analysis was performed on PDS at 1 month only, at 6 months only, and at both 1 and
155 6 months. The associations between antibiotic exposure and PDS were analyzed using three
156 models. The crude model was not adjusted for any covariates. Adjusted model 1 was adjusted for
157 age, education, household income, marital status, parity, smoking habits, alcohol consumption
158 habits, energy intake, antipyretic/analgesic drug use during pregnancy, history of gastrointestinal
159 diseases, complications during pregnancy or delivery, multiple pregnancies, low birth weight,
160 and physical anomalies in newborns. To examine the effect of psychological distress on the

161 association between antibiotic exposure and PDS, we additionally included the K6 scores as
162 continuous variables in Adjusted model 2 and observed the changes in the effect of antibiotic
163 exposure on PDS. We further included an interaction term (K6 score * antibiotic exposure) in
164 Adjusted model 2 to examine whether there is an interaction effect between the K6 scores and
165 antibiotic exposure. Interactions were considered to be significant at $p < 0.1$. The forced-entry
166 method was used to include all covariates. There was no collinearity among the exploratory
167 variables (the correlation coefficients of the exploratory variables < 0.26). Missing values for the
168 covariates were complemented via multiple imputations by chained equations. Specifically, each
169 missing value was replaced with a series of substituted plausible values by creating 10 filled-in
170 complete datasets and integrating the values according to Rubin's (1987) rule.

171 Furthermore, two sensitivity analyses were performed to assess the robustness of the
172 results of the logistic regression analyses. First, to eliminate the effect of antibiotic use on
173 different gastrointestinal conditions, we performed analyses that excluded cases with history of
174 colorectal disease (Crohn's disease or ulcerative colitis). Second, complete case analyses were
175 performed after the missing data for the covariates were excluded.

176 Subsequently, path analysis was performed to assess the mediation of psychological
177 distress (K6 scores) during pregnancy in the relationship between antibiotic exposure and PDS
178 (EPDS scores) at 1 and 6 months. The EPDS and K6 scores were included as continuous
179 variables. Figure 2 shows the path diagram. The association between antibiotic exposure and
180 PDS at 1 month had direct and indirect effects via the K6 scores. The association between
181 antibiotic exposure and the EPDS scores at 6 months had direct and indirect effects via the K6
182 scores, and the indirect effect included paths with and without the EPDS scores at 1 month. For
183 each association, the sum of the direct and indirect effects was considered as the total effect.

184 Covariates on mothers (i.e., age, education, household income, marital status, parity, smoking
185 habits, alcohol consumption habits, energy intake, antipyretic/analgesic drug use during
186 pregnancy, history of gastrointestinal diseases, complications during pregnancy or delivery, and
187 multiple pregnancies) were set to be associated with antibiotic exposure, the K6 scores, and the
188 EPDS scores at 1 and 6 months. Covariates on children (i.e., low birth weight and physical
189 anomalies in newborns) were set to be associated with the EPDS scores at 1 and 6 months. To
190 address the missing values, the direct, indirect, and total effects were estimated via Bayesian
191 estimation. The model's goodness-of-fit was evaluated via the maximum likelihood method. We
192 considered the model to fit well if the comparative fit index (CFI) was ≥ 0.95 and the root mean
193 square error of approximation (RMSEA) was ≤ 0.05 . All analyses were conducted using SPSS
194 Statistics Base, SPSS Regression, and SPSS Amos v. 27 (IBM Corp., Armonk, NY, USA).

195

196 **3 RESULTS**

197 **3.1 Participants' background characteristics**

198 A total of 103,062 mothers were registered. We excluded 37,790 of them from our analysis
199 owing to incomplete data on the key variables, cesarean section for which the use of antibiotics
200 is essential, or a history of psychiatric illness. Hence, 65,272 mothers were included (Figure 3).

201 Only a few differences in the prevalence of PDS, antibiotic exposure, and the main
202 characteristics of the mother and child were observed between the included and excluded cases.
203 Of the included mothers, 10.7% took antibiotics orally during pregnancy (see Supporting
204 Information Table S1).

205 At 1 and 6 months postpartum, 8,042 (12.3%) and 6,604 (10.1%) women were classified
206 as having experienced PDS, respectively. Table 1 presents the participants' main characteristics

207 according to having PDS at 6 months postpartum. Mothers with PDS were younger (< 25 years,
208 16.8%), less educated (< 10 years, 6.7%; 10–12 years, 36.4%), lower income earners (< 4 million
209 Japanese yen, 45.2%), unmarried (7.1%), and more likely to be smokers during pregnancy
210 (6.3%). Severe mental disorders were reported by 11.8% of the women with PDS and 1.3% of
211 those without during mid-late pregnancy. Meanwhile, psychological distress was reported by
212 53.3% and 20.5% of the women with and without PDS, respectively. By contrast, 33.5% and
213 77.3% of the women with and without PDS, respectively, were mentally stable (reported no
214 disorders or stress).

215

216 **3.2 Association between antibiotic exposure and postpartum depressive symptoms** 217 **based on the logistic regression models**

218 The results of the logistic regression analysis are shown in Table 2. Antibiotic exposure was
219 associated with a significantly increased OR for PDS at 1 and 6 months after delivery, not
220 adjusted for the covariates. In Adjusted model 1, the inclusion of the covariates decreased the
221 ORs marginally, indicating that these covariates had a small confounding effect, and antibiotic
222 exposure became nonsignificant: PDS at 1 month after delivery (OR = 1.05, 95% CI [0.97, 1.13])
223 and 6 months after delivery (OR = 1.07, 95% CI [0.99, 1.16]). When the timing of the PDS
224 assessment was classified as 1 month only, 6 months only, or 1 month and 6 months, antibiotic
225 exposure was solely associated with PDS at 6 months after delivery (OR = 1.07, 95% CI [0.97,
226 1.19], OR = 1.13, 95% CI [1.00, 1.26], and OR = 1.07, 95% CI [0.93, 1.16], respectively). The
227 two sensitivity analyses for cases with no colorectal disease and complete cases for the
228 covariates showed a similar association between PDS and antibiotic exposure (see Supporting
229 Information Table S2).

230 In Adjusted model 2, which included the K6 scores (psychological distress) as an
231 additional covariate, the association between antibiotic exposure and PDS at 6 months
232 disappeared. No interaction between antibiotic exposure and the K6 scores was observed in these
233 associations.

234

235 **3.3 Association between antibiotic exposure and postpartum depressive symptoms and** 236 **mediation of psychological distress during pregnancy based on the path analysis**

237 Path analysis was conducted to examine the effects of antibiotic exposure on the EPDS scores at
238 1 and 6 months after delivery, including the direct effects, indirect effects via the K6 scores
239 during pregnancy, and total effects (Figure 2). The model fit the data well according to all the
240 goodness-of-fit measures (CFI = 0.964, RMSEA [90% CI] = 0.036 [0.035, 0.037]). An
241 insignificant direct effect of antibiotic exposure on the EPDS scores at 1 month after delivery (β
242 = 0.003, 95% Bayesian credible interval (BCI) [-0.004, 0.009]) and a positive, significant,
243 indirect effect via the K6 scores during pregnancy were observed ($\beta = 0.011$, 95% BCI [0.008,
244 0.014]), as shown in Table 3. The results were very similar for the effect on the EPDS scores at 6
245 months. Regarding the total effects, the EPDS scores at 1 and 6 months were both increased
246 significantly by antibiotic exposure ($\beta = 0.014$, 95% BCI [0.006, 0.021] for 1 month and $\beta =$
247 0.012, 95% BCI [0.005, 0.019] for 6 months).

248

249 **4 DISCUSSION AND CONCLUSIONS**

250 Our results showed a weak association between antibiotic exposure during pregnancy and an
251 increased risk of PDS at 6 months after delivery. Nevertheless, this association disappeared when
252 adjusted for the K6 scores (psychological distress) during pregnancy in the logistic regression

253 models. However, because K6 was measured at only one time point in the second questionnaire,
254 we were unable to determine if psychological distress preceded antibiotic exposure, which would
255 indicate that K6 was a confounding variable, or if antibiotic exposure preceded psychological
256 distress, which would indicate that K6 was an intermediate variable. Therefore, we explored the
257 role of psychological distress (K6) through the path analysis, with the results suggesting that
258 increased PDS at 1 and 6 months after delivery was fully mediated by psychological distress
259 during pregnancy, not by a direct association with antibiotic exposure. However, this finding in
260 itself is not conclusive without further evidence of a causal relationship between antibiotic
261 exposure and psychological distress. This finding could be an interesting focus for future studies
262 to consider when studying the link between antibiotic exposure and PDS.

263 We found that antibiotic exposure during pregnancy was associated with PDS at 6
264 months, defined as above the cut-off value, but not at 1 month or at both 1 and 6 months. PDS
265 commonly occurs within 4 to 6 weeks after delivery and could last up to 1 or even 2 years after
266 delivery (Beck, 2006; Kettunen et al., 2014; Kikuchi et al., 2021; Norhayati et al., 2015). Some
267 PDS at 1 month after delivery can be attributed to postpartum blues, which 50–75% of new
268 mothers experience a few days after delivery and often disappear within 10 days (Beck, 2006;
269 Kettunen et al., 2014; Norhayati et al., 2015). Our findings suggest that antibiotic exposure
270 increased PDS onset, which could appear a few months after delivery, rather than early PDS,
271 which includes the temporary postpartum blues.

272 Our path analysis results indicated that antibiotic exposure during pregnancy was not
273 associated with postpartum depressive tendencies directly, but affected these tendencies through
274 psychological distress during pregnancy. It seems that antibiotic exposure during pregnancy was
275 associated with increased psychological distress during pregnancy, which was strongly

276 associated with postpartum depressive tendencies at 1 and 6 months. Several prospective studies
277 have reported that prenatal anxiety and depression are strong risk factors for PDS (Milgrom et
278 al., 2008; Sutter-Dallay et al., 2004; Underwood et al., 2017). Our analysis showed that the K6
279 scores during pregnancy were directly related to the EPDS scores at 6 months as well as at 1
280 month. This result indicates that psychological distress during pregnancy may be related to late-
281 onset postpartum depression, which is different from the temporary postpartum blues. Although
282 antibiotic exposure during pregnancy was not significantly associated with the risk of PDS at 1
283 month according to the logistic regression analysis, the results of the path analysis indicated that
284 antibiotic exposure during pregnancy contributed to an increase of postpartum depressive
285 tendencies at 1 month via increased psychological distress during pregnancy.

286 A possible explanation for the association between antibiotic exposure and
287 psychological distress during pregnancy is that the disruption of the microbiota in pregnant
288 women caused by antibiotic exposure leads to increased psychological distress during pregnancy.
289 Abundant evidence has suggested that changes in the gut microbiota increase the risk of
290 neuropsychiatric disorders (e.g., depression and anxiety), which are mediated through the gut–
291 brain axis (Evrensel & Ceylan, 2015; Liang et al., 2018; Rieder et al., 2017). The gut–brain axis
292 has been recognized to function through neural, hormonal, and immunological routes (Cryan &
293 Dinan, 2012; Foster & McVey Neufeld, 2013). Further, the GABA receptor expression plays an
294 important role in the pathogenesis of developing depression and anxiety, and could be caused by
295 the disruption of the microbiota (Carding et al., 2015). Therefore, the disruption of the
296 microbiota due to antibiotic exposure could lead to depressive symptoms.

297 Another explanation could be that a pathogenic infection that requires antibiotic
298 treatment may affect maternal mental health. It is also possible that anxiety or the guilt about the

299 effects of medication on the fetus could affect the mother's mental condition. However, since the
300 analysis model was adjusted for antipyretic/analgesic drug use during pregnancy, the effects of
301 an infection and the anxiety due to the use of medication may have been excluded. Some studies
302 have revealed the association between antibiotic treatment and higher risk of depression or other
303 mental disorders (Köhler-Forsberg et al., 2019; Liang et al., 2018; Lurie et al., 2015). Therefore,
304 antibiotic treatment during pregnancy may contribute to the risk for PDS.

305 Our results were partially consistent with those of Murphy et al. (2018), in that both
306 studies showed a relationship between antibiotic exposure during pregnancy and postpartum
307 depressive tendencies. Our data indicated a relationship between antibiotic exposure during
308 pregnancy and PDS at 6 months after delivery, whereas Murphy et al. (2018) reported an
309 association between maternal peripartum antibiotic exposure and PDS at 1 and 2 months but not
310 at 3 or 6 months. These discrepancies may be attributed to the differences in sample size, the
311 target period of antibiotic exposure, and data analysis method. We only considered antibiotic
312 exposure during pregnancy. Conversely, Murphy et al. (2018) considered antibiotic exposure
313 during pregnancy and the first 14 days postpartum. Nevertheless, our results support the
314 hypothesis that antibiotic exposure during pregnancy is a risk factor for PDS.

315 There are approximately 800,000 births in Japan each year and the period prevalence of
316 postpartum depression 6–12 months after birth was 11.5% between 1994 and 2017 (Tokumitsu et
317 al., 2020). Although the effect size was small, our data indicated an association between
318 antibiotic intake and the onset of PDS within the 6 months after delivery not adjusting for
319 prenatal psychological distress. This small increase translates into an increase by approximately
320 0.6– 0.7 % of risk for PDS at 1 month after delivery and, at 6 months after delivery.

321 Since PDS is related to a high suicide rate, difficulties in bonding with infants, harming
322 newborns, and interrupting children’s development, and is a serious public health concern
323 (Dubber et al., 2015; Grace et al., 2003; WHO, 2019; Wisner et al., 2019). Various advocacy
324 programs have been implemented in many countries. These include home visits by nurses or
325 local community health staff, interviews with clinicians, and social support (Centers for Disease
326 Control and Prevention, 2020; Kendig et al., 2017; Milgrom et al., 2008; Segre et al., 2010;
327 WHO, 2019; Wisner et al., 2019). However, the effects of antibiotic treatment on PDS are not
328 clearly understood as a risk factor in perinatal healthcare. If perinatal healthcare staff are aware
329 of the risks, they could pay more attention to providing support after antibiotic use, which may
330 eventually reduce the risk of PDS.

331 Furthermore, probiotics may help prevent and treat PDS. Although they are not same as
332 the gut microbiota, probiotics and/or prebiotics could replace the lost microbiota and improve
333 depressive symptoms (Blaser, 2016; Jang et al., 2019; Mörkl et al., 2020; Slykerman et al.,
334 2017).

335 This study has some limitations. First, the data on antibiotic exposure were drawn from a
336 self-reported questionnaire. Therefore, there may have been a non-differential misclassification
337 bias in the reporting and coding of medications. Second, we were unable to accurately determine
338 the specific type, timing, and duration of antibiotic use during pregnancy. Therefore, differences
339 in effects according to the timing or spectrum of the antibiotics could not be evaluated. Third,
340 while the reasons for antibiotic use during pregnancy and the acquisition of infection itself may
341 have also affected the mental status of the mothers, no related data were obtained. Fourth, we
342 measured K6 at only one point of time, which was in the second questionnaire; therefore, we
343 were unable to describe the causal relationship between antibiotic exposure and psychological

344 distress. Fifth, the hypothetical role of the gut microbiota in postpartum mood disorders was not
345 examined because no information on microbiota was available. Although limited evidence
346 suggests that the microbiome may contribute to PDS via a potential relationship with antibiotics,
347 this is an important area for future research. To confirm our results, future studies should use
348 more detailed data on antibiotic exposure and participants' gut microbiota. Finally, important
349 information, such as the participants previous history of stress, depression, and/or family history
350 of depression, was not obtained. This may have resulted in a shortfall in the PDS evaluation.

351 Overall, we observed a small increase in the risk of PDS at 6 months after delivery
352 among women who received antibiotics during pregnancy, which may be explained by
353 psychological distress during the antenatal period. Our study highlights a compelling focus for
354 future research that antibiotic exposure can cause psychological distress, which mediates the
355 pathway to PDS. Prospective epidemiological studies are needed to establish a causal link
356 between antibiotic exposure and antenatal psychological distress and confirm the hypothesized
357 causal pathway. Although the use of antibiotics when medically necessary does not need to be
358 changed, additional postnatal follow-ups should be considered in the future when antibiotics are
359 prescribed to pregnant women who show signs of depression. Observation after antibiotics use
360 by healthcare providers is recommended to monitor the mental health of pregnant and
361 postpartum women. Increased monitoring may reduce the development of PDS or hasten its early
362 recognition and treatment.

363 **REFERENCES**

- 364 Adynski, H., Zimmer, C., Thorp, J., & Santos, H. P. (2019). Predictors of psychological distress
365 in low-income mothers over the first postpartum year. *Research in Nursing & Health*,
366 42(3), 205–216. doi:10.1002/nur.21943
- 367 Ailes, E. C., Summers, A. D., Tran, E. L., Gilboa, S. M., Arnold, K. E., Meaney-Delman, D., &
368 Reefhuis, J. (2018). Antibiotics dispensed to privately insured pregnant women with
369 urinary tract infections—United States, 2014. *MMWR. Morbidity and Mortality Weekly*
370 *Report*, 67(1), 18–22. doi:[10.15585/mmwr.mm6701a4](https://doi.org/10.15585/mmwr.mm6701a4)
- 371 Beck, C. T. (2006). Postpartum depression: It isn't just the blues. *American Journal of Nursing*,
372 106(5), 40–51. doi:10.1097/00000446-200605000-00020
- 373 Blaser, M. J. (2016). Antibiotic use and its consequences for the normal microbiome. *Science*,
374 352(6285), 544–545. doi:[10.1126/science.aad9358](https://doi.org/10.1126/science.aad9358)
- 375 Carding, S., Verbeke, K., Vipond, D. T., Corfe, B. M., & Owen, L. J. (2015). Dysbiosis of the
376 gut microbiota in disease. *Microbial Ecology in Health and Disease*, 26(1), 26191.
377 doi:10.3402/mehd.v26.26191
- 378 Centers for Disease Control and Prevention. (2020). Vital signs identifying maternal
379 depression—Missed opportunities to support moms. Retrieved from
380 [https://archive.cdc.gov/www_cdc_gov/reproductivehealth/vital-signs/identifying-](https://archive.cdc.gov/www_cdc_gov/reproductivehealth/vital-signs/identifying-maternal-depression/VS-May-2020-Maternal-Depression_h.pdf)
381 [maternal-depression/VS-May-2020-Maternal-Depression_h.pdf](https://archive.cdc.gov/www_cdc_gov/reproductivehealth/vital-signs/identifying-maternal-depression/VS-May-2020-Maternal-Depression_h.pdf)
- 382 Cox, J. L., Holden, J. M., & Sagovsky, R. (1987). Detection of postnatal depression.
383 Development of the 10-item Edinburgh Postnatal Depression Scale. *British Journal of*
384 *Psychiatry*, 150, 782–786. doi:[10.1192/bjp.150.6.782](https://doi.org/10.1192/bjp.150.6.782)

385 Crumeyrolle-Arias, M., Jaglin, M., Bruneau, A., Vancassel, S., Cardona, A., Daugé, V., Naudon
386 L., & Rabot, S. (2014). Absence of the gut microbiota enhances anxiety-like behavior and
387 neuroendocrine response to acute stress in rats. *Psychoneuroendocrinology*, *42*, 207–217.
388 <http://dx.doi.org/10.1016/j.psyneuen.2014.01.014>

389 Cruz-Pereira, J. S., Rea, K., Nolan, Y. M., O’Leary, O. F., Dinan, T. G., & Cryan, J. F. (2020).
390 Depression’s unholy trinity: Dysregulated stress, immunity, and the microbiome. *Annual*
391 *Review of Psychology*, *71*, 49–78. doi:10.1146/annurev-psych-122216-011613

392 Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: The impact of the gut
393 microbiota on brain and behaviour. *Nature Reviews Neuroscience*, *13*(10), 701–712.
394 [doi:10.1038/nrn3346](https://doi.org/10.1038/nrn3346)

395 Dubber, S., Reck, C., Müller, M., & Gawlik, S. (2015). Postpartum bonding: The role of
396 perinatal depression, anxiety and maternal-fetal bonding during pregnancy. *Archives of*
397 *Women’s Mental Health*, *18*(2), 187–195. [doi:10.1007/s00737-014-0445-4](https://doi.org/10.1007/s00737-014-0445-4)

398 Evrensel, A., & Ceylan, M. E. (2015). The gut-brain axis: The missing link in depression.
399 *Clinical Psychopharmacology and Neuroscience*, *13*(3), 239–244.
400 [doi:10.9758/cpn.2015.13.3.239](https://doi.org/10.9758/cpn.2015.13.3.239)

401 Fawcett, E. J., Fairbrother, N., Cox, M. L., White, I. R., & Fawcett, J. M. (2019). The prevalence
402 of anxiety disorders during pregnancy and the postpartum period: A multivariate
403 Bayesian meta-analysis. *Journal of Clinical Psychiatry*, *80*(4), 18r12527.
404 [doi:10.4088/JCP.18r12527](https://doi.org/10.4088/JCP.18r12527)

405 Ferrer, M., Méndez-García, C., Rojo, D., Barbas, C., & Moya, A. (2017). Antibiotic use and
406 microbiome function. *Biochemical Pharmacology*, *134*, 114–126.
407 [doi:10.1016/j.bcp.2016.09.007](https://doi.org/10.1016/j.bcp.2016.09.007)

408 Foster, J. A., & McVey Neufeld, K. (2013). Gut-brain axis: How the microbiome influences
409 anxiety and depression. *Trends in Neurosciences*, 36(5), 305–312.
410 [doi:10.1016/j.tins.2013.01.005](https://doi.org/10.1016/j.tins.2013.01.005)

411 Furukawa, T. A., Kawakami, N., Saitoh, M., Ono, Y., Nakane, Y., Nakamura, Y., Kikkawa, T.,
412 et al. (2008). The performance of the Japanese version of the K6 and K10 in the World
413 Mental Health Survey Japan. *International Journal of Methods in Psychiatric Research*,
414 17(3), 152–158. [doi:10.1002/mpr.257](https://doi.org/10.1002/mpr.257)

415 Gelaye, B., Rondon, M. B., Araya R., & Williams, M. A. (2016). Epidemiology of maternal
416 depression, risk factors, and child outcomes in low-income and middle-income countries.
417 *Lancet Psychiatry*, 3(10), 973–982. [doi:10.1016/S2215-0366\(16\)30284-X](https://doi.org/10.1016/S2215-0366(16)30284-X)

418 Ghaedrahmati, M., Kazemi, A., Kheirabadi, G., Ebrahimi, A., & Bahrami, M. (2017).
419 Postpartum depression risk factors: A narrative review. *Journal of Education and Health*
420 *Promotion*, 6, 60. [doi:10.4103/jehp.jehp_9_16](https://doi.org/10.4103/jehp.jehp_9_16)

421 Grace, S. L., Evindar, A., & Stewart, D. E. (2003). The effect of postpartum depression on child
422 cognitive development and behavior: A review and critical analysis of the literature.
423 *Archives of Women's Mental Health*, 6(4), 263–274. [doi:10.1007/s00737-003-0024-6](https://doi.org/10.1007/s00737-003-0024-6)

424 Halbreich, U., & Karkun, S. (2006). Cross-cultural and social diversity of prevalence of
425 postpartum depression and depressive symptoms. *Journal of Affective Disorders*, 91(2–
426 3), 97–111. [doi:10.1016/j.jad.2005.12.051](https://doi.org/10.1016/j.jad.2005.12.051)

427 Jang H., Lee, H., Jang S., Han, M., & Kim, D. (2018). Evidence for interplay among
428 antibacterial-induced gut microbiota disturbance, neuro-inflammation, and anxiety in
429 mice. *Mucosal Immunology*, 11(5), 1386–1397. doi.org/10.1038/s41385-018-0042-3

430 Jang, H., Lee, K., & Kim, D. (2019). The preventive and curative effects of *Lactobacillus reuteri*
431 NK33 and *Bifidobacterium adolescentis* NK98 on immobilization stress-induced
432 anxiety/depression and colitis in mice. *Nutrients*, *11*(4), 819. doi:10.3390/nu11040819

433 Kawamoto, T., Nitta, H., Murata, K., Toda, E., Tsukamoto, N., Hasegawa, M., Yamagata, Z., et
434 al. (2014). Working Group of the Epidemiological Research for Children's
435 Environmental Health. Rationale and study design of the Japan environment and
436 children's study (JECS). *BMC Public Health*, *14*(1), 25. doi:[10.1186/1471-2458-14-25](https://doi.org/10.1186/1471-2458-14-25)

437 Kendig, S., Keats, J. P., Hoffman, M. C., Kay, L. B., Miller, E. S., Simas, T. A. M., Lemieux, L.
438 A., et al. (2017). Consensus bundle on maternal mental health: Perinatal depression and
439 anxiety. *Obstetrics and Gynecology*, *129*(3), 422–430.
440 doi:10.1097/AOG.0000000000001902

441 Kessler, R. C., Andrews, G., Colpe, L. J., Hiripi, E., Mroczek, D. K., Normand, S. L. T., Walters,
442 E. E., & Zaslavsky, A. M. (2002). Short screening scales to monitor population
443 prevalences and trends in non-specific psychological distress. *Psychological Medicine*,
444 *32*(6), 959–976. doi:[10.1017/s0033291702006074](https://doi.org/10.1017/s0033291702006074)

445 Kettunen, P., Koistinen, E., & Hintikka, J. (2014). Is postpartum depression a homogenous
446 disorder: Time of onset, severity, symptoms and hopelessness in relation to the course of
447 depression. *BMC Pregnancy and Childbirth*, *14*, 402. doi:[10.1186/s12884-014-0402-2](https://doi.org/10.1186/s12884-014-0402-2)

448 Khanlari, S., Eastwood, J., Barnett, B., Naz, S., & Ogbo F. A. (2019). Psychosocial and obstetric
449 determinants of women signalling distress during Edinburgh Postnatal Depression Scale
450 (EPDS) screening in Sydney, Australia. *BMC Pregnancy and Childbirth*, *19*(1), 407.
451 doi:[10.1186/s12884-019-2565-3](https://doi.org/10.1186/s12884-019-2565-3)

- 452 Kikuchi, S., Murakami, K., Obara, T., Ishikuro, M., Ueno, F., Noda, A., Onuma, T., et al. (2021).
453 One-year trajectories of postpartum depressive symptoms and associated psychosocial
454 factors: Findings from the Tohoku Medical Megabank Project Birth and Three-
455 Generation Cohort Study. *Journal of Affective Disorders*, 295, 632–638.
456 [doi:10.1016/j.jad.2021.08.118](https://doi.org/10.1016/j.jad.2021.08.118)
- 457 Klainin, P., & Arthur, D. G. (2009). Postpartum depression in Asian cultures: A literature
458 review. *International Journal of Nursing Studies*, 46(10), 1355–1373.
459 [doi:10.1016/j.ijnurstu.2009.02.012](https://doi.org/10.1016/j.ijnurstu.2009.02.012)
- 460 Klein-Petersen, A. W., Köhler-Forsberg, O., & Benros, M. E. (2021). Infections, antibiotic
461 treatment and the microbiome in relation to schizophrenia. *Schizophrenia Research*, 234,
462 71–77. [doi:10.1016/j.schres.2019.11.033](https://doi.org/10.1016/j.schres.2019.11.033)
- 463 Köhler-Forsberg, O., Petersen, L., Gasse, C., Mortensen, P. B., Dalsgaard, S., Yolken, R. H.,
464 Mors, O., & Benros, M. E. (2019). A nationwide study in Denmark of the association
465 between treated infections and the subsequent risk of treated mental disorders in children
466 and adolescents. *JAMA Psychiatry*, 76(3), 271–279.
467 [doi:10.1001/jamapsychiatry.2018.3428](https://doi.org/10.1001/jamapsychiatry.2018.3428)
- 468 Liang, S., Wu, X., Hu, X., Wang, T., & Jin, F. (2018). Recognizing depression from the
469 microbiota–gut–brain axis. *International Journal of Molecular Sciences*, 19(6), 1592.
470 [doi:10.3390/ijms19061592](https://doi.org/10.3390/ijms19061592)
- 471 Lurie, I., Yang, Y., Haynes, K., Mamtani, R., & Boursi, B. (2015). Antibiotic exposure and the
472 risk for depression, anxiety, or psychosis: A nested case-control study. *Journal of*
473 *Clinical Psychiatry*, 76(11), 1522–1528. [doi:10.4088/JCP.15m09961](https://doi.org/10.4088/JCP.15m09961)

474 Mayer, E. A., Tillisch, K., & Gupta, A. (2015). Gut/brain axis and the microbiota. *Journal of*
475 *Clinical Investigation*, 125(3), 926–938. doi:[10.1172/JCI76304](https://doi.org/10.1172/JCI76304)

476 Milgrom, J., Gemmill, A. W., Bilszta, J. L., Hayes, B., Barnett, B., Brooks, J., Ericksen,
477 J., Ellwood, D., & Buist, A. (2008). Antenatal risk factors for postnatal depression: A
478 large prospective study. *Affective Disorders*, 108(1–2), 147–157.
479 doi:[10.1016/j.jad.2007.10.014](https://doi.org/10.1016/j.jad.2007.10.014)

480 Ministry of Health, Labour and Welfare of Japan. (2019). *Sukoyaka Oyako 21 (Dai 2ji) no*
481 *chukan hyouka tou ni kansuru kentoukai houkokusho (an) [Report from Investigation*
482 *Committee about Mid-term Evaluation of “Healthy Parents and Children 21 (2nd)”]*.
483 Retrieved from <https://www.mhlw.go.jp/content/11908000/000541865.pdf>.

484 Mörkl, S., Butler, M. I., Holl, A., Cryan, J. F., & Dinan, T. G. (2020). Probiotics and the
485 microbiota-gut-brain axis: Focus on psychiatry. *Current Nutrition Reports*, 9(3), 171–
486 182. <https://doi.org/10.1007/s13668-020-00313-5>

487 Murphy, J. R., Paul, S., Dunlop, A. L., & Corwin, E. J. (2018). Maternal peripartum antibiotic
488 exposure and the risk of postpartum depression. *Research in Nursing and Health*, 41,
489 369–377. doi:[10.1002/nur.21881](https://doi.org/10.1002/nur.21881)

490 Norhayati, M. N., Hazlina, N. H. N., Asrenee, A. R., & Emilin, W. M. A.W. (2015). Magnitude
491 and risk factors for postpartum symptoms: A literature review. *Journal of Affective*
492 *Disorders*, 175, 34–52. doi:[10.1016/j.jad.2014.12.041](https://doi.org/10.1016/j.jad.2014.12.041)

493 O’Hara, M. W., & McCabe, J. E. (2013). Postpartum depression: Current status and future
494 directions. *Annual Review of Clinical Psychology*, 9, 379–407. doi:[10.1146/annurev-](https://doi.org/10.1146/annurev-clinpsy-050212-185612)
495 [clinpsy-050212-185612](https://doi.org/10.1146/annurev-clinpsy-050212-185612)

496 Okano, T., Murata, M., Masuji, F., Tamaki, R., Nomura, J., Miyaoka, H., & Kitamura, T. (1996).
497 Nihonban Ejinbara sango utsubyou jikohyoukahyou (EPDS) no shinraisei to datousei
498 [Validation and reliability of Japanese version of the Edinburgh Postnatal Depression
499 Scale (EPDS)]. *Archives of Psychiatric Diagnostics and Clinical Evaluation*, 7(4), 525–
500 533.

501 Payne, J. L., & Maguire, J. (2019). Pathophysiological mechanisms implicated in postpartum
502 depression. *Frontiers in Neuroendocrinology*, 52, 165–180.
503 doi:10.1016/j.yfrne.2018.12.001

504 Pouranayatihosseiniabad, M., Taylor, M., Hawrelak, J. A., Peterson, G. M., Veal, F., Ling, T.,
505 Williams, M., Whatley, M., Ahdieh, K., & Mirkazemi, C. (2023). Maternal antibiotic
506 exposure and the risk of developing antenatal or postpartum depressive symptoms: The
507 maternal experience study protocol. *Methods and Protocols*, 6(5), 98.
508 doi:10.3390/mps6050098

509 Pouranayatihosseiniabad, M., Taylor, M., Hawrelak, J. A., Peterson, G. M., Veal, F., Ling, T.,
510 Williams, M., Whatley, M., Ahdieh, K., & Mirkazemi C. (2024). Maternal antibiotic
511 exposure and the risk of developing antenatal depressive symptoms. *Journal of Clinical*
512 *Medicine*, 13(5), 1434. doi:10.3390/jcm13051434

513 Rhee, S. H., Pothoulakis, C., & Mayer, E. A. (2009). Principles and clinical implications of the
514 brain-gut-enteric microbiota axis. *Nature Reviews. Gastroenterology and Hepatology*,
515 6(5), 306–314. doi:10.1038/nrgastro.2009.35

516 Rieder, R., Wisniewski, P. J., Alderman, B. L., & Campbell, S. C. (2017). Microbes and mental
517 health: A review. *Brain, Behavior, and Immunity*, 66, 9–17.
518 doi:10.1016/j.bbi.2017.01.016

519 Righetti-Veltema, M., Bousquet, A., & Manzano, J. (2003). Impact of postpartum depressive
520 symptoms on mother and her 18-month-old infant. *European Child & Adolescent*
521 *Psychiatry*, 12(2), 75–83. doi:10.1007/s00787-003-0311-9

522 Rubin, D., B. (1987). *Multiple imputation for nonresponse in surveys*. Hoboken, New Jersey:
523 John Wiley & Sons. doi:10.1002/9780470316696.

524 Santos, F., Sheehy, O., Perreault, S., Ferreira, E., & Bérard, A. (2012). Trends in anti-infective
525 drugs use during pregnancy. *Journal of Population Therapeutics and Clinical*
526 *Pharmacology*, 19(3), e460–e465.
527 <https://www.jptcp.com/index.php/jptcp/article/view/411/343>

528 Schwartz, D. J., Langdon, A. E., & Dantas, G. (2020). Understanding the impact of antibiotic
529 perturbation on the human microbiome. *Genome Medicine*, 12(1), 82.
530 doi:10.1186/s13073-020-00782-x

531 Segre, L. S., O’Hara, M. W., Arndt, S., & Beck, C. T. (2010). Screening and counseling for
532 postpartum depression by nurses: The women’s views. *MCN American Journal of*
533 *Maternal/Child Nursing*, 35(5), 280–285. doi:10.1097/NMC.0b013e3181e62679

534 Slykerman, R. F., Hood, F., Wickens, K., Thompson, J. M. D., Barthow, C., Murphy, R., et al.,
535 Probiotic in Pregnancy Study Group. (2017). Effect of *Lactobacillus rhamnosus* HN001
536 in pregnancy on postpartum symptoms of depression and anxiety: A randomised double-
537 blind placebo-controlled trial. *EBio Medicine*, 24, 159–165.
538 [doi:10.1016/j.ebiom.2017.09.013](https://doi.org/10.1016/j.ebiom.2017.09.013)

539 Smolina, K., Hanley, G. E., Mintzes, B., Oberlander, T. F., & Morgan, S. (2015). Trends and
540 determinants of prescription drug use during pregnancy and postpartum in British

541 Columbia, 2002–2011: A population-based cohort study. *PLOS One*, *10*(5), e0128312.
542 [doi:10.1371/journal.pone.0128312](https://doi.org/10.1371/journal.pone.0128312)

543 Sutter-Dallay, A. L., Giaccone-Marcasche, V., Glatigny-Dallay, E., & Verdoux, H. (2004).
544 Women with anxiety disorders during pregnancy are at increased risk of intense postnatal
545 depressive symptoms: A prospective survey of the MATQUID cohort. *European*
546 *Psychiatry*, *19*(8), 459–463. [doi:10.1016/j.eurpsy.2004.09.025](https://doi.org/10.1016/j.eurpsy.2004.09.025)

547 Tokumitsu, K., Sugawara, N., Maruo, K. I., Suzuki, T., Shimoda, K., & Yasui-Furukori, N.
548 (2020). Prevalence of perinatal depression among Japanese women: A meta-analysis.
549 *Annals of General Psychiatry*, *19*, 41. [doi:10.1186/s12991-020-00290-7](https://doi.org/10.1186/s12991-020-00290-7)

550 Underwood, L., Waldie, K. E., D’Souza, S., Peterson, E. R., & Morton, S. M. B. (2017). A
551 longitudinal study of pre-pregnancy and pregnancy risk factors associated with antenatal
552 and postnatal symptoms of depression: Evidence from growing up in New Zealand.
553 *Maternal and Child Health Journal*, *21*(4), 915–931. [doi:10.1007/s10995-016-2191-x](https://doi.org/10.1007/s10995-016-2191-x)

554 Wisner, K. L., Miller, E. S., & Tandon, D. (2019). Attention to prevention: Can we stop perinatal
555 depression before it starts? *JAMA Psychiatry*, *76*(4), 355–356.
556 [doi:10.1001/jamapsychiatry.2018.4085](https://doi.org/10.1001/jamapsychiatry.2018.4085)

557 World Health Organization (WHO). (2019). Mental health and substance use. Retrieved from
558 [https://www.who.int/teams/mental-health-and-substance-use/promotion-](https://www.who.int/teams/mental-health-and-substance-use/promotion-prevention/maternal-mental-health)
559 [prevention/maternal-mental-health](https://www.who.int/teams/mental-health-and-substance-use/promotion-prevention/maternal-mental-health)

560 Yokoyama, Y., Takachi, R., Ishihara, J., Ishii, Y., Sasazuki, S., Sawada, N., Shinozawa, Y.,
561 Tanaka, J., Kato, E., Kitamura, K., Nakamura, K., & Tsugane, S. (2016). Validity of short
562 and long self-administered Food Frequency Questionnaires in ranking dietary intake in
563 middle-aged and elderly Japanese in the Japan Public Health Center-Based Prospective

564 Study for the Next Generation (JPHC-NEXT) Protocol Area. *Journal of Epidemiology*,
565 26(8), 420–432. doi:10.2188/jea.JE20150064

566 TABLES

567 TABLE 1. Participants' main characteristics according to their postpartum depressive symptoms

568 at 6 months postpartum (N = 65,272)

	Postpartum depressive symptoms at 6 months postpartum			
	Yes		No	
	(EPDS ^a ≥ 9)		(EPDS ^a < 9)	
	n	(%)	n	(%)
Number	6,604	(10.1)	58,668	(89.9)
Maternal characteristics				
Age at delivery (years)				
< 25	1,108	(16.8)	5,234	(8.9)
25–29	2,086	(31.6)	16,824	(28.7)
30–34	2,056	(31.1)	21,608	(36.8)
≥ 35	1,353	(20.5)	15,000	(25.6)
Missing	1	(0.0)	2	(0.0)
Education (years)				
< 10	442	(6.7)	2,104	(3.6)
10–12	2,406	(36.4)	17,447	(29.7)
≥ 13	3,695	(56.0)	38,808	(66.1)
Missing	61	(0.9)	309	(0.5)
Annual household income (million Japanese yen)				
< 4	2,986	(45.2)	20,744	(35.4)

4 to < 6	1,831	(27.7)	18,658	(31.8)
6 to < 8	770	(11.7)	9,124	(15.6)
≥ 8	444	(6.7)	6,250	(10.7)
Missing	573	(8.7)	3,892	(6.6)
Marital status at study enrollment				
Married	6,097	(92.3)	56,348	(96.0)
Neither married, divorced, nor widowed	471	(7.1)	2,108	(3.6)
Missing	36	(0.5)	212	(0.4)
Parity				
0	2,661	(40.3)	23,074	(39.3)
1	2,547	(38.6)	22,430	(38.2)
≥ 2	1,229	(18.6)	11,818	(20.1)
Missing	167	(2.5)	1,346	(2.3)
Smoking				
Never	3,484	(52.8)	35,379	(60.3)
Former	2,632	(39.9)	20,792	(35.4)
Smoking at mid-late pregnancy	414	(6.3)	2,018	(3.4)
Missing	74	(1.1)	479	(0.8)
Alcohol consumption				
Never	2,139	(32.4)	19,733	(33.6)
Former	4,183	(63.3)	36,869	(62.8)
Drinking at mid-late pregnancy	215	(3.3)	1,581	(2.7)

Missing	67	(1.0)	485	(0.8)
Energy intake (kcal, in tertile)				
Low (< 1,475)	2,021	(30.6)	19,761	(33.7)
Medium (1,475–1,943)	1,967	(29.8)	20,053	(34.2)
High (\geq 1,944)	2,615	(39.6)	18,851	(32.1)
Missing	1	(0.0)	3	(0.0)
Antipyretic/analgesic drug use during pregnancy				
Yes	1,496	(22.7)	11,188	(19.1)
History of gastrointestinal diseases				
Yes	841	(12.7)	5,639	(9.6)
Complications during pregnancy or delivery				
Yes	2,987	(45.2)	25,366	(43.2)
Missing	91	(1.4)	954	(1.6)
Multiple pregnancy				
Yes	12	(0.2)	100	(0.2)
Low birth weight (< 2,500 g)				
Yes	420	(6.4)	3,492	(6.0)
Missing	0	(0.0)	11	(0.0)
Physical anomalies in newborns				
Yes	400	(6.1)	3,213	(5.5)
Missing	121	(1.8)	1,098	(1.9)
Maternal psychological distress at mid-late pregnancy (K6 score ^b)				
Mentally stable (< 5)	2,215	(33.5)	45,358	(77.3)

Psychological distress (5–12)	3,521	(53.3)	12,021	(20.5)
Severe mental disorder (> 12)	782	(11.8)	787	(1.3)
Missing	86	(1.3)	502	(0.9)

569 *Note:* ^a EPDS, Edinburgh Postnatal Depression Scale; ^b K6, Kessler Psychological Distress Scale.

570 **TABLE 2.** The association between antibiotic exposure and postpartum depressive symptoms at 1 and 6 months postpartum based on
 571 the binomial and multinomial logistic regression models (N = 65,272)

Postpartum depressive symptoms (EPDS ^a score \geq 9)	Cases		Crude model		Adjusted model 1		Adjusted model 2		<i>p</i> value for interaction (K6 scores ^d ×antibiotics)
	n	(%)	OR ^b	95% CI ^c	OR	95% CI	OR	95% CI	
At 1 month ^e	8,042	(12.3)	1.09	[1.01, 1.17]	1.05	[0.97, 1.13]	0.96	[0.89, 1.05]	0.938
At 6 months ^e	6,604	(10.1)	1.17	[1.08, 1.26]	1.07	[0.99, 1.16]	0.98	[0.90, 1.07]	0.178
At 1 month only ^f	4,543	(7.0)	1.06	[0.96, 1.16]	1.07	[0.97, 1.19]	1.01	[0.91, 1.11]	0.691
At 6 months only ^f	3,105	(4.8)	1.20	[1.07, 1.34]	1.13	[1.00, 1.26]	1.05	[0.93, 1.18]	0.322
At both 1 and 6 months ^f	3,499	(5.4)	1.15	[1.03, 1.28]	1.07	[0.93, 1.16]	0.92	[0.81, 1.04]	0.689

572 *Note:* Adjusted model 1 includes age, education, household income, marital status, parity, smoking, alcohol consumption, energy
 573 intake, antipyretic/analgesic drug use during pregnancy, history of gastrointestinal diseases, complications during pregnancy or
 574 delivery, multiple pregnancies, low birth weight, and physical anomalies in newborns as covariates. Adjusted model 2 includes the K6
 575 score in addition to the variables in Adjusted model 1.

576 ^a EPDS, Edinburgh Postnatal Depression Scale; ^b OR, odds ratio; ^c CI, confidence interval; ^d K6, Kessler Psychological Distress Scale;

577 ^e Analysis using binomial logistic regression; ^f Analysis using multinomial logistic regression.

578 **Bold letters indicate that the estimates in which the 95% CI does not include 0.**

579 **TABLE 3.** Relationship between antibiotic exposure (by mid-late pregnancy) and PDS at 1 and
 580 6 months via psychological distress (at mid-late pregnancy) estimated by mediation analysis (N
 581 = 65,272)

limita	Path	Standardized estimate	
		β	[95% BCI ^c]
At 1 month	Direct effect	Exposure → EPDS scores at 1 month	0.003 [-0.004, 0.009]
	Indirect effect	Exposure → K6 ^b scores → EPDS scores at 1 month	0.011 [0.008, 0.014]
	Total effect		0.014 [0.006, 0.021]
At 6 months	Direct effect	Exposure → EPDS scores at 6 months	0.000 [-0.006, 0.005]
	Indirect effect (1 + 2)	1. Exposure → K6 scores → EPDS scores at 6 months	0.013 [0.008, 0.018]
		2. Exposure → K6 scores → EPDS scores at 1 month → EPDS scores at 6 months	
	Total effect		0.012 [0.005, 0.019]

582 *Note:* ^a EPDS, Edinburgh Postnatal Depression Scale; ^b K6, Kessler Psychological Distress Scale;
 583 ^c BCI, Bayesian credible interval. Bold letters indicate that the estimates in which the 95% BCI
 584 does not include 0.

585 **SUPPORTING INFORMATION**586 **TABLE S1. Comparison of the major characteristics of the included and excluded participants**

Maternal characteristics	Included (n = 65,272)			Excluded (n = 37,790)		
	Valid N	n	(%)	Valid N	n	(%)
Postpartum depressive symptoms (EPDS^a score)						
At 1 month	65,272			30,261		
< 9		57,230	(87.7)		24,723	(81.7)
≥ 9		8,042	(12.3)		5,538	(18.3)
At 6 months	65,272			25,874		
< 9		58,668	(89.9)		21,842	(84.4)
≥ 9		6,604	(10.1)		4,032	(15.6)
Psychological distress at mid-late pregnancy (K6^b score)						
	64,684			32,475		
Mentally stable (< 5)		47,573	(73.5)		21,454	(66.1)
Psychological distress (5–12)		15,542	(24.0)		9,384	(28.9)
Severe mental disorder (> 12)		1,569	(2.4)		1,637	(5.0)
Antibiotic use during pregnancy	65,272			32,191		
No		58,290	(89.3)		28,405	(88.2)
Yes		6,982	(10.7)		3,786	(11.8)
Age at delivery (years)	65,269			35,814		
< 25		6,342	(9.7)		3,811	(10.6)
25–29		18,910	(29.0)		8,881	(24.8)

30–34	23,664	(36.3)	12,028	(33.6)
≥ 35	16,353	(25.1)	11,094	(31.0)
Education (years)	64,902		32,576	
< 10	2,546	(3.9)	2,180	(6.7)
10–12	19,853	(30.6)	10,831	(33.2)
≥ 13	42,503	(65.5)	19,565	(60.1)

587

588 *Note:* ^a EPDS, Edinburgh Postnatal Depression Scale; ^b K6, Kessler Psychological Distress Scale.

589 TABLE S2. Sensitivity analyses for the association between antibiotic exposure and postpartum
 590 depressive symptoms at 1 and 6 months after delivery

Postpartum depressive symptoms (EPDS ^a score \geq 9)		Number of cases	Crude model		Adjusted model 1	
	OR ^b		95% CI ^c	OR	95% CI	
No colorectal disease (imputed, n = 65,105)						
At 1 month ^d	8,019	1.09	[1.01, 1.17]	1.05	[0.97, 1.13]	
At 6 months ^d	6,590	1.17	[1.08, 1.26]	1.07	[0.99, 1.16]	
At 1 month only ^e	4,530	1.06	[0.96, 1.17]	1.07	[0.97, 1.19]	
At 6 months only ^e	3,101	1.20	[1.08, 1.34]	1.13	[1.00, 1.26]	
At both 1 and 6 months ^e	3,489	1.15	[1.03, 1.28]	1.04	[0.93, 1.16]	
Complete case (n = 57,020)						
At 1 month ^d	6,822	1.08	[1.00, 1.17]	1.05	[0.94, 1.17]	
At 6 months ^d	5,642	1.19	[1.10, 1.30]	1.14	[1.01, 1.29]	
At 1 month only ^e	3,862	1.03	[0.93, 1.15]	0.99	[0.92, 1.06]	
At 6 months only ^e	2,682	1.22	[1.09, 1.37]	1.14	[1.04, 1.24]	
At both 1 and 6 months ^e	2,960	1.18	[1.05, 1.32]	1.06	[0.94, 1.19]	


591 *Note:* Adjusted model 1 includes age, education, household income, marital status, parity,
 592 smoking habits, alcohol consumption habits, energy intake, antipyretic/analgesic drug use during
 593 pregnancy, history of gastrointestinal diseases, complications during pregnancy or delivery,
 594 multiple pregnancies, low birth weight, and physical anomalies in newborns as covariates.
 595 ^a EPDS, Edinburgh Postnatal Depression Scale; ^b OR, odds ratio; ^c CI, confidence interval; ^d
 596 Analysis using binomial logistic regression; ^e Analysis using multinomial logistic regression. The
 597 models were adjusted for all the covariates.

598 Bold letters indicate that the estimates in which the 95% CI does not include 0.

599 **FIGURE CAPTIONS**


600 Figure 1. Flowchart of the data collection for antibiotic exposure, postpartum depressive
601 symptoms, and psychological distress

602 *Note:* T1 = Term 1; T2 = Term 2; K6 = Kessler Psychological Distress Scale; EPDS = Edinburgh
603 Postnatal Depression Scale




604
605 Figure 2. Path model for the relationship between antibiotic exposure and psychological distress
606 (K6 scores) during pregnancy and PDS (EPDS scores)

607 *Note:* “Covariates on mothers” included age, education, household income, marital status, parity,
608 smoking habits, alcohol consumption habits, energy intake, antipyretic/analgesic drug use during
609 pregnancy, history of gastrointestinal diseases, complications during pregnancy or delivery, and
610 multiple pregnancies. “Covariates on children” included low birth weight and physical anomalies
611 in newborns. Values indicate standardized β and Bayesian credible intervals.



612

613 Figure 3. Selection of the participants



Research in Nursing & Health vol. 1098240x No.0 (online)

2025年1月8日公表済

DOI : 10.1002/nur.22442